Vaccinations are among the most effective tools in public health for preventing infectious diseases. Vaccines elicit an immune response that reduces the chance of infection, severity of illness, and onward transmission. The World Health Organization Director-General Tedros Adhanom Ghebreyesus World Health Organization reports that vaccination prevents an estimated 2 to 3 million deaths every year, illustrating the large-scale lifesaving effect of immunization programs.
Measuring vaccine effect
Two related but distinct measures are important: vaccine efficacy and vaccine effectiveness. Vaccine efficacy comes from randomized clinical trials and measures protection under ideal conditions, while vaccine effectiveness reflects how well a vaccine reduces disease in the real world. For example, the measles vaccine shows about 93 percent efficacy after one dose and about 97 percent after two doses, a figure reported by the Centers for Disease Control and Prevention. Influenza vaccines illustrate seasonal variability; effectiveness can range widely from year to year, commonly between about 10 percent and 60 percent depending on how well the vaccine strains match circulating viruses.
Clinical trials, observational studies, and population surveillance together provide evidence. Vaccine researchers such as Paul A. Offit Children's Hospital of Philadelphia have summarized how these different data sources converge to show robust reductions in disease incidence, hospitalizations, and deaths after vaccine introduction. Individual-level protection and population-level impact are both measured to assess public health benefit.
Real-world impact and challenges
The consequences of widespread vaccination are dramatic. Global polio cases have fallen by more than 99 percent since the Global Polio Eradication Initiative began in 1988, demonstrating how sustained immunization campaigns can nearly eliminate a pathogen. Routine childhood vaccines have eliminated smallpox and pushed many diseases to low levels or near eradication in many regions. At the same time, effectiveness at preventing disease depends on coverage: high uptake creates herd immunity, lowering transmission even for people who cannot be vaccinated. Where coverage drops, outbreaks can and do return, as seen in localized measles resurgences linked to gaps in vaccination.
Causes that limit vaccine effectiveness in practice include biological factors such as pathogen evolution and waning immunity, programmatic factors like cold chain failures or incomplete schedules, and social factors including mistrust and unequal access. These influences vary by cultural and territorial context; remote or conflict-affected areas often face logistical barriers, while vaccine hesitancy in certain communities reflects deep social and historical dynamics that public health programs must address respectfully.
Understanding effectiveness also requires attention to consequences beyond immediate disease prevention: vaccines can reduce long-term disability, lower healthcare costs, and support economic resilience by preventing workforce losses. Nuanced policy responses combine evidence-based communication, equitable delivery systems, and surveillance to detect changing pathogen dynamics. When these elements align, vaccines remain one of the most powerful, evidence-backed interventions in medicine.